NIH Weekly Funding Opportunities and Policy Notices

Friday, May 12, 2017 - 12:10am
Funding Opportunity PA-17-286 from the NIH Guide for Grants and Contracts. The purpose of the administrative supplement is to provide support for NIH-funded investigators to participate in an entrepreneurship training course, the Concept to Clinic: Commercializing Innovation (C3i) Program. The C3i Program is designed to provide medical device innovators with the specialized business frameworks and essential tools for successful translation of biomedical technologies from the lab (concept) to the market (clinic). Through this program, the NIH fosters the development and commercialization of early-stage biomedical technologies by engaging investigators who are interested in better understanding the value of their innovation in addressing an unmet market need. The curriculum and customized mentoring provided by the C3i Program are intended to guide investigators as they assess the commercial viability and potential business opportunity for their innovation. Prospective applicants are strongly encouraged to contact NIH Scientific/Research staff for more information about the program before applying.
Friday, May 12, 2017 - 12:05am
Funding Opportunity RFA-FD-17-012 from the NIH Guide for Grants and Contracts. The Food and Drug Administration's (FDA), Office of Regulatory Affairs (ORA), Office of Resource Management (ORM), Division of Human Resource Development (DHRD) is announcing this Funding Opportunity Announcement (FOA) for a Cooperative Agreement Grant. The goals of this Cooperative Agreement Grant are to continue the development of the Integrated Food Safety System (IFSS) National Curriculum Standard (NCS) for the laboratory competency and curriculum frameworks, further work on the development and validation of competency statements, and create, develop and deliver courses to IFSS laboratorians nationwide. Under FSMA Section 209, FDA is directed to improve the training of state, local, territorial and tribal food safety officials and set standards and administer training and education programs to ensure a competent work force doing comparable work.
Thursday, May 11, 2017 - 11:18pm
Funding Opportunity RFA-DA-18-008 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage research projects that investigate covalent RNA modifications in HIV/AIDS and substance use disorders. Identifying modifications involved in HIV function as well as understanding the mechanisms involved and how these processes interact with chronic drug exposure could lay the foundation for the development of future novel therapeutics to treat HIV in patients with SUDs.
Thursday, May 11, 2017 - 11:18pm
Funding Opportunity RFA-DA-18-009 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage research projects that investigate covalent RNA modifications in HIV/AIDS and substance use disorders. Identifying modifications involved in HIV function as well as understanding the mechanisms involved and how these processes interact with chronic drug exposure could lay the foundation for the development of future novel therapeutics to treat HIV in patients with SUDs.
Thursday, May 11, 2017 - 7:21am
Notice NOT-AA-17-004 from the NIH Guide for Grants and Contracts
Thursday, May 11, 2017 - 7:18am
Notice NOT-CA-17-058 from the NIH Guide for Grants and Contracts
Thursday, May 11, 2017 - 7:00am
Notice NOT-CA-17-059 from the NIH Guide for Grants and Contracts
Wednesday, May 10, 2017 - 10:52am
Notice NOT-NR-17-024 from the NIH Guide for Grants and Contracts
Wednesday, May 10, 2017 - 8:43am
Funding Opportunity PAR-17-276 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA), issued by NINDS, is to invite currently awarded NIH StrokeNet centers and potential new stroke centers to participate as a Regional Coordinating Stroke Center in the NIH StrokeNet clinical trials network. The goal of this existing network is to maximize efficiencies to develop, promote and conduct high-quality, multi-site clinical trials focused on key interventions in stroke prevention, treatment, and recovery with the objective to have a balanced portfolio between all three approaches. Exploratory Phase 1/2 and confirmatory Phase 3 clinical trials as well as biomarker-validation studies that are immediately preparatory to trials will be coordinated through separate National Clinical Coordinating (NCC) and National Data Management Centers (NDMC).
Wednesday, May 10, 2017 - 8:26am
Funding Opportunity PAR-17-275 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose exploratory and confirmatory clinical trials focused on promising interventions, as well as biomarker-or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery. The program will utilize the cooperative agreement mechanism to enable milestone-drive projects.
Wednesday, May 10, 2017 - 8:26am
Funding Opportunity PAR-17-277 from the NIH Guide for Grants and Contracts. This FOA encourages requests for access to research resources for multi-site exploratory and confirmatory clinical trials focused on promising interventions, as well as biomarker-or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery. Successful applicants will be given access to the NIH StrokeNet infrastructure. Following peer review, NINDS will prioritize trials among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.

Pages